Lutetium Lu 177 Vipivotide Tetraxetan

Novartis sales grew 12% on a constant currency basis, with core operating income up 21%, in the third quarter of 2023 compared with this time last year, according to a company press release.

CHICAGO — Lutetium Lu 177 vipivotide tetraxetan is a viable option for certain men with advanced prostate cancer, according to study results presented at ASCO Annual Meeting.

Novartis temporarily suspended production at two of its radioligand therapy production sites.

The FDA approved lutetium Lu 177 vipivotide tetraxetan for treatment of certain men with advanced prostate cancer.